**NCCP Chemotherapy Regimen**

**CISplatin, Methotrexate and vinBLAStine Therapy**

**INDICATIONS FOR USE:**

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium</td>
<td></td>
<td>C67</td>
<td>Hospital</td>
</tr>
</tbody>
</table>

**TREATMENT:**
The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Treatment is administered as described below every 21 days for a maximum of 3 cycles or until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.

<table>
<thead>
<tr>
<th>Admi n Order</th>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1,8</td>
<td>Methotrexate</td>
<td>30mg/m²</td>
<td>IV Bolus</td>
<td>Every 21 days for up to 3 cycles</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1,8</td>
<td>VinBLAStine</td>
<td>4mg/m²</td>
<td>IV infusion</td>
<td>50ml 0.9% NaCl over 15 min</td>
<td>Every 21 days for up to 3 cycles</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>CISplatin</td>
<td>100mg/m²</td>
<td>IV infusion</td>
<td>500ml 0.9% NaCl over 120mins</td>
<td>Every 21 days for up to 3 cycles</td>
</tr>
<tr>
<td>4</td>
<td>2,9</td>
<td>Folinic acid</td>
<td>15mg</td>
<td>PO or IV</td>
<td>Every 6 hrs (total 4 doses) to start 24hr after methotrexate on day 1 and day 8</td>
<td>Every 21 days for up to 3 cycles</td>
</tr>
</tbody>
</table>

*VinBLAStine is a neurotoxic chemotherapeutic agent. Refer to NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer [here](#).

* Pre and post hydration therapy required for CISplatin
  
  See local hospital policy recommendations.
  
  Suggested prehydration for CISplatin therapy:
  1. Administer 10mmol magnesium sulphate (MgSO₄) (±/− KCl 20mmol/L if indicated) in 1000 ml sodium chloride 0.9% over 60 minutes.
  2. Administer CISplatin as described above.
  3. Post hydration: Administer 1000 ml 0.9% NaCl over 60mins.
  4. Mannitol 10% may be used as per local policy to induce diuresis, although there is no conclusive evidence that this is required. The routine use of furosemide to increase urine flow is not recommended unless there is evidence of fluid overload [3,4].

**ELIGIBILITY:**

- Indications as above
- ECOG 0-1

NCCP Regimen: CISplatin, Methotrexate and VinBLAStine Therapy (CMV)-14 days

Published: 20/06/2016

Review: 10/06/2025

Version number: 3

Tumour Group: Genitourinary

NCCP Regimen Code: 00337

ISMO Contributor: Prof Maccon Keane

Page 1 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer).

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens).
EXCLUSIONS:
- Hypersensitivity to methotrexate, vinBLASTine, CISplatin or any of the excipients
- Moderate/severe renal impairment (creatinine clearance < 60 mL/min)
- Pregnancy and Lactation
- Pre-existing neuropathies ≥ grade 2
- Significant hearing impairment/tinnitus

PRESCRIPTIVE AUTHORITY:
The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:
Baseline tests:
- FBC, renal and liver profile
- Audiology and creatinine clearance if clinically indicated

Regular tests:
- FBC, renal and liver profile prior to each cycle
- FBC and renal profile Day 8

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant.

Haematological:
Table 1: Dose modification for haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Platelets (x10^9/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1.5 and ≥100</td>
<td>100% Dose</td>
<td></td>
</tr>
<tr>
<td>&lt;1.5 or &lt;100</td>
<td>Hold* until recovery</td>
<td></td>
</tr>
<tr>
<td>Febrile neutropenia or ANC &lt; 0.5 or &lt; 50</td>
<td>Hold *until recovery then 75% of previous dose</td>
<td></td>
</tr>
</tbody>
</table>

*Do not start a new cycles until ANC ≥1.5 x 10^9/L and platelets ≥100 x10^9/L
Renal and Hepatic Impairment:

### Table 2: Dose modifications in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methotrexate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CrCl (ml/min)</td>
<td>Dose</td>
<td>Bilirubin (micromol/L)</td>
</tr>
<tr>
<td>&gt;80</td>
<td>100%</td>
<td>&lt;50</td>
</tr>
<tr>
<td>60-80</td>
<td>65%</td>
<td>51-85</td>
</tr>
<tr>
<td>45-60</td>
<td>50%</td>
<td>&gt;85</td>
</tr>
<tr>
<td>30-45</td>
<td>Clinical decision</td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>Contra-indicated</td>
<td></td>
</tr>
</tbody>
</table>

**vinBLASTine**

No dose reduction necessary

<table>
<thead>
<tr>
<th>Drug</th>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CISplatin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CrCl (ml/min)</td>
<td>Dose</td>
<td>Bilirubin (micromol/L)</td>
</tr>
<tr>
<td>≥60</td>
<td>100%</td>
<td>26-51</td>
</tr>
<tr>
<td>45-59</td>
<td>75%</td>
<td>&gt;51</td>
</tr>
<tr>
<td>&lt;45</td>
<td>Consider CARBOplatin</td>
<td></td>
</tr>
</tbody>
</table>

Management of adverse events:

### Table 3: Dose Modification of CMV Therapy for Adverse Events

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurotoxicity</td>
<td>Reduce dose of CISplatin and vinBLASTine by 25% dose.</td>
</tr>
<tr>
<td>Grade 2 present at start of next cycle</td>
<td>Discontinue CISplatin and vinBLASTine</td>
</tr>
<tr>
<td>Grade 3</td>
<td></td>
</tr>
</tbody>
</table>

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:**

- CISplatin: High
- Methotrexate: Low
- vinBLASTine: Minimal (Refer to local policy).

**PREMEDICATIONS:** None usually required

**OTHER SUPPORTIVE CARE:**

- Hydration prior and post CISplatin administration (Reference local policy or see recommendations above). Patient should be encouraged to drink large quantities of liquids for 24 hours after the CISplatin infusion to ensure adequate urine secretion.
- Prophylactic laxatives may be required to prevent constipation related to the use of vinca alkaloids.

---

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at http://www.hse.ie/Eng/Disclaimer. This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens.
NCCP Chemotherapy Regimen

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS
The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- Neutropenia: Fever or other evidence of infection must be assessed promptly and treated appropriately.
- Pleural effusion or ascites: Methotrexate should be used with caution in patients with pleural effusions or ascites, as methotrexate may accumulate in third space fluid compartments.
- Extravasation: vinBLAstine is a vesicant which may cause pain and tissue necrosis if extravasated. (Refer to local extravasation guidelines).
- Hypersensitivity: Hypersensitivity reactions have been reported with CISplatin.
- Renal Toxicity: Nephrotoxicity is common with CISplatin. Strongly encourage oral hydration. If oral hydration is not possible (e.g. excessive nausea), IV hydration is indicated. Avoid nephrotoxic drugs such as aminoglycoside antibiotics where possible. Where treatment with nephrotoxic drugs must be used, monitor renal function.
- Ototoxicity and sensory neural damage: These are associated with CISplatin therapy. They should be assessed by history prior to each cycle.

DRUG INTERACTIONS:
- NSAIDs may decrease the clearance of methotrexate by decreasing its renal perfusion and tubular secretion thus increasing its toxicity.
- Sulphonamides and penicillins may displace bound methotrexate from plasma protein increasing serum methotrexate levels and its toxicity.
- Concomitant administration of drugs that cause folate deficiency may lead to increased methotrexate toxicity.
- Ciprofloxacin may inhibit renal tubular transport of methotrexate, increasing serum methotrexate levels and its toxicity.
- Probenecid may inhibit renal excretion of methotrexate, increasing serum methotrexate levels and its toxicity.
- Co-administration of CISplatin has been reported to cause higher plasma concentrations of vinBLAstine.
- Erythromycin may increase the toxicity of vinBLAstine.
- CISplatin may potentiate the nephrotoxic and ototoxic effects of loop diuretics and aminoglycosides so concurrent use should be avoided.
- Current drug interaction databases should be consulted for more information.

ATC CODE:
Methotrexate - L01BA01
vinBLAstine - L01CA01
CISplatin - L01XA01

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
NCCP Chemotherapy Regimen

REFERENCES:


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20/06/2016</td>
<td></td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>2</td>
<td>20/06/2018</td>
<td>Updated with new NCCP regimen format, standardisation of treatment table updated with revised CISplatin hydration regimen recommendations</td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>3</td>
<td>10/06/2020</td>
<td>Reviewed. Standardisation treatment table and dose modifications in hepatic and renal impairment.</td>
<td>Prof Maccon Keane</td>
</tr>
</tbody>
</table>

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.